Palliative treatment of germ cell cancer.

Abstract	Most patients with metastatic germ-cell cancer (GCC) can be cured by cisplatin-based combination chemotherapy. Yet, about 10-15% of metastatic GCC patients will eventually die of their disease. This narrative review focuses on treatment options when cure is no longer realistic.
Authors	Christoph Oing, Patrizia Giannatempo, Friedemann Honecker, Karin Oechsle, Carsten Bokemeyer, Jörg Beyer
Journal	Cancer treatment reviews (Cancer Treat Rev) Vol. 71 Pg. 102-107 (Dec 2018) ISSN: 1532-1967 [Electronic] Netherlands
PMID	30415106 (Publication Type: Journal Article, Review)
Copyright	Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Chemical References	Antineoplastic Agents
Topics	Antineoplastic Agents (therapeutic use) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Bone Neoplasms (secondary, therapy) Brain Neoplasms (secondary, therapy) Humans Immunotherapy (methods) Molecular Targeted Therapy (methods) Neoplasms, Germ Cell and Embryonal (pathology, therapy) Palliative Care (methods) Peripheral Nervous System Diseases (etiology) Psychosocial Support Systems

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!